Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

as well as the launches of Mim8 and amycretin. What do I expect from Eli Lilly in the long term? I estimate Eli Lilly's non-GAAP EPS and revenue growth will be higher than Novo Nordisk's over the ...

Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio by developing Mim8 for hemophilia A, with plans to submit it for regulatory approval soon. Alhemo (concizumab) has been ...